Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Hanes

Interventional Pain Medicine Saint Augustine, FL Medical Doctor

NPI 1760708473 CMS profile 1288517

1100 Plantation Island Dr S Ste 220, Saint Augustine, FL 32080

Open in the dashboard

General payments

$91,420

579 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,000 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Michael Hanes of Saint Augustine, FL is reported in the CMS Open Payments database as having received $91,420 across 579 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,541 74
2024 General $7,151 61
2023 General $3,096 77
2022 General $23,941 103
2021 General $11,486 125
2020 General $8,023 53
2019 General $33,183 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Hanes
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Michael Hanes were reported at $4,541. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Michael Hanes Interventional Pain Medicine median Middle half National median
2019 $33,183 $684 $216–$2,079 $163
2020 $8,023 $382 $122–$1,109 $114
2021 $11,486 $552 $167–$1,554 $132
2022 $23,941 $605 $187–$1,924 $149
2023 $3,096 $671 $195–$1,915 $160
2024 $7,151 $684 $206–$1,837 $164
2025 $4,541 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $31,848 143 payments
  2. Medtronic USA, Inc. $22,109 57 payments
  3. Medtronic, Inc. $21,968 95 payments
  4. Boston Scientific Corporation $5,287 68 payments
  5. MML US, Inc. $2,555 18 payments
  6. Relievant Medsystems, Inc. $1,096 13 payments
  7. Painteq LLC $967 12 payments
  8. Saluda Medical Americas, Inc. $537 10 payments
  9. AbbVie, Inc. $500 34 payments
  10. Stimwave Technologies Incorporated $460 9 payments
  11. Other $4,093 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,600 22 payments
  2. Food and Beverage $19,643 497 payments
  3. Consulting Fee $16,855 10 payments
  4. Travel and Lodging $9,444 41 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,460 4 payments
  6. Education $419 5 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $16,179 44 payments
  2. INTELLIS ADAPTIVESTIM $12,346 44 payments
  3. RESTORE Spinal Cord Neurostimulation $10,587 13 payments
  4. PROCLAIM Neuromodulation $8,523 40 payments
  5. INTELLIS $7,972 16 payments
  6. RESTORE Spinal Cord Neurostimulation $6,690 11 payments
  7. PROCLAIM Neuromodulation $4,733 8 payments
  8. ADAPTIVESTIM $2,587 22 payments
  9. ReActiv8 $2,555 18 payments
  10. KYPHON EXPRESS II KYPHOPAK TRAY $2,003 22 payments
  11. Other $20,320 401 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

5,842

Median for Pain Management: 951

Drug cost

$163,174

Median for Pain Management: $26,034

Branded share of claims

49%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Percocet Oxycodone Hcl/Acetaminophen Brand 14 $43,851
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,479 $33,651
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,126 $30,626
Xtampza Er Oxycodone Myristate Brand 25 $9,706
Pregabalin Generic 599 $9,088
Oxycodone Hcl Generic 559 $7,252
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 28 $4,616
Tramadol Hcl Generic 717 $4,196
Gabapentin Generic 232 $3,103
Morphine Sulfate Er Morphine Sulfate Brand 162 $2,710

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$601,629

Of which drugs: $1,038

Medicare patients

660

Average age 74

Services billed

6,080

405 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 42%
Depression 35%
Diabetes 31%
Chronic kidney disease 31%
COPD 27%
Osteoporosis 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 159 1,044 $804
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 138 2,331 $209

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $43
$43 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $35
$35 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $23
$23 — —
UBRELVY
  • AbbVie, Inc. $8
$8 — —
QULIPTA
  • AbbVie, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

579 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record